story of the week
Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Platinum-Resistant or Platinum-Refractory Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial
JAMA Oncol 2023 May 25;[EPub Ahead of Print], RW Holloway, AA Mendivil, JE Kendrick, LN Abaid, JV Brown, J LeBlanc, ND McKenzie, KM Mori, S AhmadFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.